Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Immune-mediated enterocolitis? 858 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 858 reports of Immune-mediated enterocolitis have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 1.0% of all adverse event reports for PEMBROLIZUMAB.

858
Reports of Immune-mediated enterocolitis with PEMBROLIZUMAB
1.0%
of all PEMBROLIZUMAB reports
150
Deaths
560
Hospitalizations

How Dangerous Is Immune-mediated enterocolitis From PEMBROLIZUMAB?

Of the 858 reports, 150 (17.5%) resulted in death, 560 (65.3%) required hospitalization, and 81 (9.4%) were considered life-threatening.

Is Immune-mediated enterocolitis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 858 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Immune-mediated enterocolitis?

NIVOLUMAB (1,289) IPILIMUMAB (988) CARBOPLATIN (307) PACLITAXEL (188) DURVALUMAB (165) ATEZOLIZUMAB (156) LENVATINIB (143) PEMETREXED (129) BEVACIZUMAB (92) TREMELIMUMAB\TREMELIMUMAB-ACTL (63)

Which PEMBROLIZUMAB Alternatives Have Lower Immune-mediated enterocolitis Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Immune-mediated enterocolitis Reports All Drugs Causing Immune-mediated enterocolitis PEMBROLIZUMAB Demographics